( NYSE:ABBV )

News from AbbVie A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Aug 03, 2017, 15:28 ET AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved MAVYRET™...


Jul 28, 2017, 11:16 ET Tratamento para Hepatite C da AbbVie Estará Disponível pelo SUS

- Único tratamento para Hepatite C, da nova geração (sem uso de interferon), de curta duração (12 semanas), a combinar agentes antivirais que...


Jul 28, 2017, 10:57 ET European Commission Grants AbbVie's MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorization for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Commission has granted marketing authorization for...


Jul 28, 2017, 07:42 ET AbbVie Reports Second-Quarter 2017 Financial Results

AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2017. "We are pleased with the continued strength of our...


Jul 21, 2017, 09:36 ET AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients with Chronic Non-infectious Anterior Uveitis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of...


Jul 10, 2017, 08:01 ET AbbVie to Host Second-Quarter 2017 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its second-quarter 2017 financial results on Friday, July 28, 2017, before the market opens. AbbVie will host a...


Jun 28, 2017, 07:42 ET AbbVie é a companhia farmacêutica com melhor reputação, segundo estudo do Reputation Institute

Reputation Institute, com sede em Boston e mais de 20 anos em pesquisa de reputação corporativa em todo o mundo, apurou a biofarmacêutica AbbVie...


Jun 26, 2017, 13:00 ET Funcionários da AbbVie Doam Mais de 26.000 Horas de Trabalho em uma Única Semana em Benefício de Comunidades ao Redor do Mundo

- AbbVie Brasil se junta aos seus colegas ao redor do mundo para fazer a diferença na vida de pessoas menos assistidas - Mais de 6.000 funcionários...


Jun 26, 2017, 09:45 ET 6,000 Employees in More Than 50 Countries Join Together as #AbbVieGivesBack

AbbVie, a global biopharmaceutical company, and its key partners celebrate the launch of the fourth annual "Week of Possibilities," with more than...


Jun 23, 2017, 08:47 ET AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of...


Jun 22, 2017, 15:52 ET AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.64 per share. The cash dividend is payable Aug. 15,...


Jun 13, 2017, 08:30 ET AbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors

AbbVie (NYSE: ABBV), a global biopharmaceutical company, and Principia Biopharma Inc., a private, clinical-stage biopharmaceutical company,...


Jun 07, 2017, 07:56 ET AbbVie's Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Phase 3 Study in Rheumatoid Arthritis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced positive top-line results from the Phase 3 SELECT-NEXT clinical trial...


Jun 05, 2017, 07:00 ET New Data Presented at ASCO 2017 Finds IMBRUVICA® (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients

IMBRUVICA (ibrutinib) reduced cells that may play an important role in the survival and proliferation of chronic lymphocytic leukemia (CLL),...


Jun 02, 2017, 14:30 ET Cerca de 25 Milhões de brasileiros têm dor de barriga frequente. Para tratar, a maioria se automedica, revela pesquisa DATAFOLHA, patrocinada pela AbbVie

Cerca de 25 milhões de brasileiros, com mais de 16 anos, têm dor de barriga ou diarreia frequente (várias vezes ao ano), que tentam tratar com...


May 24, 2017, 08:00 ET AbbVie to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 38th Annual Global Healthcare Conference on Tuesday, June 13, 2017. Bill Chase, executive...


May 19, 2017, 08:00 ET AbbVie to Present at the Jefferies 2017 Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Jefferies 2017 Global Healthcare Conference on Thursday, June 8, 2017. Bill Chase, executive vice...


May 17, 2017, 17:00 ET AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced it will present data about the company's portfolio of approved and...


May 17, 2017, 12:00 ET AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix at the World Congress on Endometriosis

AbbVie (NYSE: ABBV), a global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced that data...


May 14, 2017, 17:00 ET IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results from an analysis of data pooled from three Phase 3 studies...


May 09, 2017, 11:00 ET AbbVie Announces Positive Phase 2 Study Results for Upadacitinib (ABT-494), an Investigational JAK1-Selective Inhibitor, in Crohn's Disease

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced promising results from CELEST, a Phase 2, randomized, double-blind,...


May 05, 2017, 12:43 ET AbbVie to Present at the UBS Global Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Monday, May 22, 2017. Richard A. Gonzalez, chairman of the board...


May 04, 2017, 09:00 ET AbbVie Demonstrates Leadership in Gastroenterology and Hepatology with New Data and Late-Breaking Studies to be Presented at Digestive Disease Week®

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data from 20 abstracts in gastroenterology and hepatology programs...


Apr 27, 2017, 07:38 ET AbbVie Reports First-Quarter 2017 Financial Results

AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2017. "AbbVie delivered strong first quarter results, with...